Biosensors International Group is a medical device company that specializes in developing, manufacturing and licensing technologies for use in interventional cardiology procedures and critical care. The company has manufacturing facilities in Singapore and The Netherlands, and it operates R&D centres in the United States. In May 2005, the company was listed in the Mainboard of the Singapore Exchange (SGX).
To enter the China market, Biosensors have set up a joint-venture with Hong Kong listed Shandong Weigao to market and distribute coronary stents in China.
As one of the few companies with proprietary drug-eluting stent technology, Biosensors also obtains revenues through licensing its technologies to other medical device companies like Terumo, Guidant, and specialty-stent providers like Devax, Inc. and Xtent, Inc.
Biosensors' new stent technologies includes the BioMatrix drug-eluting stent which utilizes a proprietary biodegradable polymer and Biolimus A9 drug on its S-Stent platform. Clinical trials are still undergoing at the moment though the company is confident that it will obtain CE Mark approval for this product.
US Patent Issued to Biosensors International Group on Sept. 25 for "Indirect-Release Electrolytic Implant Delivery Systems" (California Inventors)
Oct 01, 2012; ALEXANDRIA, Va., Oct. 1 -- United States Patent no. 8,273,116, issued on Sept. 25, was assigned to Biosensors International Group...